Embecta Securities Fraud Class Action
Analysis based on 233 articles · First reported Jul 01, 2026 · Last updated Aug 18, 2026
The securities fraud class action and the underlying 57.8% stock drop have severely damaged investor confidence in Embecta, leading to a sharp decline in its market capitalization. The litigation and potential settlement costs, along with reduced guidance and dividend cut, are likely to weigh on Embecta's stock price and financial performance in the near term.
Embecta Corp., a medical device company that produces insulin pens and pen needles, is facing a securities fraud class action lawsuit. The lawsuit alleges that Embecta and certain officers made materially false and misleading statements regarding the company's fiscal 2026 guidance and the stability of its pen needle business. Specifically, the company touted its pen needle portfolio as 'incredibly resolute' while allegedly knowing of significant competitive share loss and market softness. On May 5, 2026, Embecta reported second quarter fiscal 2026 results that missed guidance, with revenue declining over 14%, and slashed its full-year 2026 guidance by approximately 43% at the midpoint. The company also cut its quarterly dividend by 93%, from $0.15 to $0.01 per share. Following this news, Embecta's stock price plummeted 57.8% in a single day, from $9.25 to $3.90 per share. Multiple law firms, including Schall Brown & Schwartz LLP, Bronstein, Gewirtz & Grossman, LLC, Faruqi & Faruqi, and others, have filed or announced investigations into the company. The class period is from November 25, 2025 to May 4, 2026, and the lead plaintiff deadline is August 17, 2026. The case is pending in the U.S. District Court for the District of New Jersey.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard